Nearly 90% of those with scleroderma have Raynaud’s symptoms. This is why Raynaud’s can be a “red flag” that helps lead to diagnosis and treatment of scleroderma. And for Aneila, dx…
Read More
February is Raynaud's Awareness Month (#RaynaudsAwarenessMonth), so let’s discuss the relationship between Raynaud's phenomenon (#RaynaudsPhenomenon) and #scleroderma. Raynaud’s phenomenon is a common condition, and most people with Raynaud’s will not develop scleroderma....
Read More
Research News Alert: SRF-funded researcher Dr. Howard Chang and his collaborators have made a breakthrough discovery that sheds light on why women are more likely than men to develop certain...
Read More
February is Rare Disease Awareness Month. It's an opportunity for us to come together and raise awareness about what it means to live with a rare disease like #scleroderma. To...
Read More
Give a big round of applause to the SRF Cure Crew—in 2023 alone, they raised more than $158,000 for research! The Cure Crew is a grassroots group of volunteers that...
Read More
For our first edition of 2024, we're putting the new in eNews! In this edition, we introduced our first ever Chief Medical Officer, Dr. Greg Gordon, gave updates on novel...
Read More
Dr. Gordon will have oversight over the SRF’s global clinical trial program CONQUEST and will contribute to the research program across the SRF portfolio San Francisco, CA (January 25, 2024)…
In 2018, the SRF launched the CONQUER Registry (COllaborative National Quality and Efficacy Registry) – a first-of-its-kind longitudinal, nationwide patient registry and biosample repository aimed at improving care and developing...
Read More
FDA clears IND to launch CONQUEST trial platform with initial focus on Interstitial Lung Disease Secondary to Scleroderma (SSc-ILD) SCLERODERMA RESEARCH FOUNDATION (SRF) holds the IND as trial Sponsor Sanofi...
Read More
In our last eNews of the year, read about exciting research updates, like how CONQUEST has recieved the FDA's OK to proceed, and how CONQUER has already result in 6...
Read More
